Kalaris Therapeutics, Inc.
KLRS
$7.31
-$0.40-5.19%
| 12/31/2023 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 498.00K | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 3.46M | ||||
| Operating Income | -3.46M | ||||
| Income Before Tax | -3.47M | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -3.47M | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -3.47M | ||||
| EBIT | -3.46M | ||||
| EBITDA | -- | ||||
| EPS Basic | -0.54 | ||||
| Normalized Basic EPS | -0.34 | ||||
| EPS Diluted | -0.54 | ||||
| Normalized Diluted EPS | -0.34 | ||||
| Average Basic Shares Outstanding | 6.45M | ||||
| Average Diluted Shares Outstanding | 6.45M | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||
